NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLC
Question
NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLC
Direct answer
Peer-reviewed publication of 42% ORR and 16.0-month median OS de-risks clinical development milestones and raises commercial pipeline valuation for RVMD. — bullish pressure on RVMD via clinical pipeline de-risking following peer-reviewed NEJM publication.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-03
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLC”, revision 1, evidence through 2026-09-03. https://marketontology.com/catalysts/2026-09-03/nejm-publishes-revolution-medicines-phase-1-2-data-showing-42-orr-in-nsclc-28993d
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| RVMD | ▲Bull | 1–4 weeks | clinical pipeline de-risking following peer-reviewed NEJM publication | 69 |
NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLC
Peer-reviewed publication of 42% ORR and 16.0-month median OS de-risks clinical development milestones and raises commercial pipeline valuation for RVMD. — bullish pressure on RVMD via clinical pipeline de-risking following peer-reviewed NEJM publication.
NEJM published Phase 1/2 data showing 42% ORR and 16.0 months median OS for RASONQUE.
- SourceNEJM published Phase 1/2 data showing 42% ORR and 16.0 months median OS for RASONQUE.
- TransmissionPeer-reviewed publication of 42% ORR and 16.0-month median OS de-risks clinical development milestones and raises commercial pipeline valuation for RVMD.
- SummaryNEJM published Phase 1/2 clinical data for RVMD's daraxonrasib in RAS mutant NSCLC. The study demonstrated a 42% objective response rate and 16.0 months median overall survival.
- RVMDDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- RVMD closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- RVMD price vs. pre-event level
- RVMD volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer · POLYGON NEWS · 2026-09-02
Related catalysts
- 2026-09-03Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJMRVMD
- 2026-09-03Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJMRVMD
- 2026-09-03NEJM Publishes Revolution Medicines Phase 1/2 Lung Cancer DataRVMD
- 2026-09-03NEJM Publishes Revolution Medicines Phase 1/2 Data for Daraxonrasib in Lung CancerRVMD
- 2026-09-03NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo SurvivalRVMD
- 2026-09-03Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJMRVMD
- 2026-09-03Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM with 42% ORRRVMD
- 2026-08-27FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic CancerIMRX RVMD
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.